Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

6990

Peringkat dalam Saham #1583
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company,... Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the Peopleโ€™s Republic of China and internationally. The companyโ€™s product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC targeting advanced solid tumors; SKB410/MK-3120, a novel Nectin-4 ADC targeting advanced solid tumors; and SKB571/MK-2750, a novel bsADC primarily targeting various solid tumors, such as LC and CRC. The company also develops SKB518, SKB535/MK-6204 and SKB445, which are novel ADC drugs with potential FIC targets; SKB500 and SKB501, which are novel ADC drugs with verified targets but differentiated payload-linker strategies; SKB107, an RDC targeting tumor bone metastases; Tagitanlimab, PD-L1 mAb for its immunotherapy franchise; Cetuximab N01, a recombinant EGFR human-mouse chimeric mAb; A400, a novel selective RET inhibitor; and A296, a novel small molecule STING agonist. It has license and collaboration arrangements with Merck Sharp & Dohme LLC; Harbour BioMed Therapeutics Limited; Windward Bio AG; and Ellipses Pharma Limited. The company has a strategic partnership with Crescent Biopharma, Inc. The company was incorporated in 2016 and is headquartered in Chengdu, the Peopleโ€™s Republic of China. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.
Harga Saham
$57.07
Kapitalisasi Pasar
$13.64B
Perubahan (1 hari)
-5.37%
Perubahan (1 tahun)
-2.19%
Negara
CN
Perdagangan Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990)

Kategori

Healthcare
Jumlah saham beredar untuk Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990)
Jumlah saham beredar per October 2026: 0
Menurut laporan keuangan terbaru dan harga saham Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., jumlah saham beredar saat ini adalah 0. Pada akhir October 2026, perusahaan memiliki 0 saham beredar. Jumlah saham beredar biasanya dipengaruhi oleh pemecahan saham dan pembelian kembali saham.
Riwayat saham beredar untuk Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990) dari 2021 hingga 2026
Saham beredar pada akhir setiap tahun
Tahun Saham Beredar Mengubah
2025 230.54M 4.01%
2024 221.65M 20.70%
2023 183.63M -14.92%
2022 215.83M 133.44%
2021 92.46M 0.00%
Saham beredar untuk perusahaan serupa atau pesaing
Perusahaan Saham Beredar Perbedaan Negara
253.90M -
US
396.00M -
US
478.91M -
AU
0.00 -
BE
62.19M -
NL